Breaking News Instant updates and real-time market news.

SYRS

Syros Pharmaceuticals

$10.06

-0.135 (-1.32%)

07:38
08/07/18
08/07
07:38
08/07/18
07:38

Syros Pharmaceuticals has sufficient cash, cash equivalents to fund into 2020

Based on its current plans, Syros believes that its existing cash, cash equivalents and marketable securities will be sufficient to fund its planned operating expenses and capital expenditure requirements into 2020.

  • 07

    Aug

  • 14

    Aug

SYRS Syros Pharmaceuticals
$10.06

-0.135 (-1.32%)

10/23/17
ROTH
10/23/17
INITIATION
Target $15
ROTH
Neutral
Syros Pharmaceuticals initiated with a Neutral at Roth Capital
Roth Capital analyst Jotin Marango started Syros Pharmaceuticals with a Neutral rating and $15 price target saying it is maturing into a solid company, but value-driving proof-of-concept may take a little longer.
10/31/17
PIPR
10/31/17
INITIATION
Target $30
PIPR
Overweight
Syros Pharmaceuticals assumed with an Overweight at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff assumed coverage of Syros Pharmaceuticals with an Overweight rating and raised his price target for the shares to $30 from $20. The analyst sees the company creating value by expanding its clinical pipeline and signing new partnerships.
11/01/17
PIPR
11/01/17
NO CHANGE
PIPR
Overweight
Syros trading lower on lack of data, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff attributes the pullback today in shares of Syros Pharmaceuticals to the lack of clinical data in the online abstract, but the analyst notes this is just a placeholder. Syros will report Phase II data on SY-1425 monotherapy in biomarker-selected relapsed/refractory Acute Myeloid Leukemia and higher-risk Myelodysplastic Syndromes patients, as well as lower-risk, transfusion-dependent MDS patients in a poster at the American Society of Hematology meeting on December 10, Tenthoff tells investors in a research note. He reiterates an Overweight rating on the shares with a $30 price target.
07/17/18
PIPR
07/17/18
NO CHANGE
Target $28
PIPR
Overweight
Piper reiterates Overweight on Syros after call with oncologists
After hosting a call with two hematologic oncologists to highlight the unmet need to treat myelodysplastic syndromes and acute myeloid leukemia, Piper Jaffray analyst Edward Tenthoff reiterates an Overweight rating on shares of Syros Pharmaceuticals with a $28 price target. The analyst notes the company is conducting a Phase II study for SY-1425 in combination with azacitidine or anti-CD38 antibody Darzalex to treat intermediate to high-risk MDS or AML patients with data likely in Q4. Tenthoff remains confident in Syros' combination strategies in the ongoing study.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.